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Left ventricular (LV) endocardial pacing is a relatively new
therapy that may offer several advantages over coronary venous
lead placement for biventricular resynchronization therapy,
including access to more regions of the LV, faster impulse
propagation, avoidance of phrenic nerve stimulation, and more
physiologic LV activation.1 We report a case of transseptal
implantation of a pacing lead in the LV chamber from a superior
approach, which was observed using direct visualization, for
better understanding of the implantation procedure and device–
tissue interactions during the procedural steps.Figure 1 External view of the experimental setup showing the right
atrium (RA), left atrium (LA), superior vena cava (SVC), aorta (Ao),
pulmonary artery (PA), left ventricle (LV), and right ventricle (RV). Access
to the heart was gained via an introducer placed in the SVC cannula.Case report
Endoscopic cameras (IplexFX, Olympus Corporation,
Tokyo, Japan) were placed within the right atrium, left
atrium (LA), and LV of a human donor heart (LifeSource, St.
Paul, MN) that was deemed not viable for transplantation.
The heart was reanimated and perfused with a clear Krebs–
Henseleit buffer according to previously described method-
ologies.2,3 The intrinsic sinus rhythm of the beating heart
was 70 bpm. An external view of the experimental setup is
shown in Figure 1 and Online Supplementary Video 1.
Initially, the right atrial septum was located using a
deﬂectable catheter, and the fossa ovalis was tented using a
dilator and a subselection catheter as viewed from the right
atrium (Figure 2A) and LA (Figure 2B) (the delivery system,
leads, and implant technique are not approved for investigational
or commercial use in the United States). The fossa ovalis thenKEYWORDS Transseptal puncture; Cardiac resynchronization therapy; Iso-
lated heart; Left ventricular pacing; Endocardial pacing
ABBREVIATIONS CRT ¼ cardiac resynchronization therapy;
LA ¼ left atrium; LV ¼ left ventricle; RF ¼ radiofrequency
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).was punctured using a radiofrequency (RF) wire (Figure 2C)
and a generator (25 W at 2 seconds), and the RF wire (Baylis
Medical Inc, Montreal, Quebec, Canada) was advanced into the
LA (Figure 2D). The dilator was subsequently placed across the
fossa ovalis within the LA using the RF wire as a guide
(Figure 2E). Next, a subselection catheter was placed over the
dilator, across the septum and into the LA (Figure 2F). After the
dilator was withdrawn, the subselection catheter was directed
toward the mitral valve, and the RF wire was advanced across
the mitral valve without impinging on the chordae tendineae or
leaﬂets (Figure 2G). Thereafter, the subselection catheter was
guided over the RFwire and across the mitral valve (Figure 2H).
The RF wire was removed, which allowed the subselection
catheter to move freely within the LV. Note that in a clinical
setting, a pressurized, continuous heparinized saline ﬂush would
then be attached to subselection catheter after removal of the RF
wire. The subselection catheter was positioned on the lateral free
wall of the LV, and an active ﬁxation lead (3830 SelectSecure,pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.01.001
Figure 2 Transseptal left ventricular end
KEY TEACHING POINTS
 Implantation of an LV endocardial lead is feasible
using a superior atrial transseptal approach.
 A catheter-based delivery system with RF wire can be
used to locate and puncture the atrial septum, and
subsequently guide/implant an active ﬁxation lead in
the LV with minimal steps.
 An LV endocardial lead can be placed without
impingement of the mitral valve.
Heart Rhythm Case Reports, Vol 1, No 3, May 2015108Medtronic Inc, Mounds View, MN) was inserted into the
catheter and ﬁxated (Figure 2I). After ﬁxation, the subselection
catheter was withdrawn to ensure that the lead was fully ﬁxated
in the myocardium. The procedure can be viewed in Online
Supplementary Video 1.Discussion
LV endocardial lead placement enables physiologic pacing
and freedom to select an optimal LV pacing site in order toocardial lead implantation sequence.
109Yang et al Visualization of a Transseptal Lead Implantimprove cardiac resynchronization therapy (CRT) out-
come.4–6 Garrigue et al7 studied 15 patients with epicardial
lead implants via the coronary sinus and compared them with
8 patients with endocardial leads placed by conventional
transseptal puncture secondary to unsuitable coronary sinus
anatomy. They reported a signiﬁcant improvement in echo-
cardiographic and Doppler variables in the patients who had
undergone endocardial pacing. In addition, Bracke et al8
reported that endocardial LV pacing improved clinical
efﬁcacy in a nonresponder who previously had been
implanted with a traditional CRT system. As such, imple-
mentation of endocardial LV pacing ultimately will depend
on safe, effective, durable instrumentation and reliable,
reproducible intraprocedural methods to identify the optimal
LV pacing site. Another key to the future success of this
pacing technique will be the ability to demonstrate signiﬁ-
cant beneﬁt of LV endocardial pacing over the risk asso-
ciated with thromboembolism in advanced heart failure
patients with chronic pacing leads in the LV. Rademakers
et al9 observed thromboembolic complications with endo-
cardial pacing; however, the risk seemed to be strongly
correlated with a subtherapeutic level of anticoagulation.
Interestingly, endocardial pacing did not aggravate mitral
regurgitation in these patients. Preliminary results from the
ALSYNC (ALternate Site Cardiac ResYNChronization)
study, which used the same techniques and delivery system
demonstrated here, indicate that implantation of an LV
endocardial pacing system is feasible, safe, and clinically
successful.10 However, long-term follow-up data are needed
to assess the long-term safety and efﬁcacy of this approach to
LV pacing/CRT.
In this case study, direct visualization aided in LV
endocardial lead placement and demonstrated the feasibility
of a novel LV endocardial lead delivery system. There was
no impingement on the chordae tendineae or leaﬂets when
the lead was placed across the mitral valve; however, the lead
may be more difﬁcult to position as precisely as when
ﬂuoroscopy is used in the clinical setting. Although place-
ment of an LV lead using direct visualization is not
representative of the visualization techniques available in aclinical setting, the images presented here have notable
educational value for both clinicians and design engineers.
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